相关实验视频

Updated: Sep 19, 2025

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

多功能串联可以调解向卵巢癌细胞的向siRNA传递

Kharimat Lora Alatise¹, Timothy Samec¹, Carleigh Coffin¹

¹Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, South Carolina 29631, United States.

ACS applied bio materials

|June 4, 2025

概括

研究人员开发了一种向的融合性,用于输送用于卵巢癌治疗的小干扰RNA (siRNA). 这种可以通过向素化激素释放激素受体 (LHRHR) 来增强siRNA向癌细胞的传递.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

融合性可以改善核酸的输送,保护其免受降解并帮助内体细胞逃逸.
使用融合性酸的核酸系统输送需要针对特定应用的精细化.
主动向策略增强了细胞和组织特异性传递,最大限度地减少了非向效应.

研究的目的:

开发一种向的融合性,LHRHR-DIV3W,用于增强向卵巢癌细胞的输送.
调查该的向黄激素释放激素受体 (LHRHR) 的能力,这种受体在卵巢癌中过度表达.
为了评估合在传递小干扰RNA (siRNAs) 进行基因沉默方面的有效性.

主要方法:

合成和表征的LHRHR-DIV3W合.合成和表征.
单分散-siRNA纳米复合物的形成及其稳定性的评估.
试验室研究涉及卵巢癌细胞系中受体特异性内化.
对向瘤基因CSNK2A1.1.的siRNA基因沉默疗效的评估

主要成果:

在生理条件下,LHRHR-DIV3W形成了稳定的单分散纳米复合体,保护siRNA.
-siRNA纳米复合体在LHRHR表达卵巢癌细胞中表现出特定的内化.
与单独的向酸相比,在合酸中组合的融合和向序列将siRNA内部化增加40%.
在OVCAR3卵巢癌细胞中实现了对瘤基因CSNK2A1的显著沉默.

结论:

结合细胞向和膜破坏功能的合质可以作为核酸治疗的有效平台.
使用像LHRHR-DIV3W这样的类的有针对性的输送系统可以提高癌症治疗的特异性和有效性.
这种方法对开发基于核酸的先进治疗方法来治疗卵巢癌和潜在的其他恶性瘤具有前景.

关键词:

这是一种RNA干扰.这是一种融合性类.黄素化激素释放激素受体 (LHRHR) 是一种一个纳米复杂的纳米.卵巢癌是发生在卵巢的癌症.质载体的载体是什么?siRNA 是一个RNA.瘤向向的目标

更多相关视频

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...